Does Risdiplam Interact with Metformin?
CDI records a moderate classification for Risdiplam and Metformin. The stored summary is: EVRYSDI may increase plasma concentrations of metformin, a MATE1/MATE2-K substrate. Avoid coadministration; if unavoidable, monitor for toxicities and consider dosage reduction. The mechanism involves inhibition of mate1 or mate2-k transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Risdiplam Class
- Survival of Motor Neuron 2 Splicing Modifier
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of MATE1 or MATE2-K transporters
What To Tell Your Doctor or Pharmacist
If you are taking Risdiplam and your doctor is considering prescribing Metformin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider